Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on the neurological and psychiatric effects of the obesity/type 2 diabetes (T2D) drug semaglutide, marketed as Ozempic and Wegovy. The first-of-its-kind study scrutinized the outcomes within a year of the first dose, focusing on T2D patients. Contrary to concerns, the research revealed no association between semaglutide and 22 distinct neuro/psychiatric conditions. Moreover, it hinted at positive implications, such as mitigating cognitive issues and nicotine addiction.
The study, published in the esteemed journal eClinicalMedicine, underscores the need for further investigation into semaglutide’s potential to treat addictions and its cognitive impact. The analysis delved into the records of over 100 million patients in the United States, with more than 20,000 of them on semaglutide. The findings indicated no heightened risk associated with the drug for a spectrum of neurological and psychiatric conditions, including dementia, depression, and anxiety.- Flcube.com
